Kiniksa Pharmaceuticals International, plc Class A (KNSA)
NASDAQ · Manufacturing · Pharmaceutical preparations
$75.08−$0.2600 (−0.35%) on the dayAs of the close; data may be delayed.
KNSA price, last 12 months
Key stats
- Previous close
- $75.34
- Open
- $75.59
- Day range
- $74.53 – $76.00
- 52-week range
- $35.20 – $82.94
- Volume
- 243.6K
- Avg volume (20 days)
- 531K
- Market cap
- $5.9B
Performance
1W−2.8%
1M−4.6%
3M+26.8%
6M+60.5%
YTD+82.0%
1Y+108.0%
vs S&P 500, 1Y+91.3 pts
Technicals and fundamentals
About Kiniksa Pharmaceuticals International, plc Class A
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $5.9B